Santa Clara, CA, July 24, 2013 — ProteinSimple today introduced the FluorChem R system as the next member of the FluorChem product family. The FluorChem R system is a fully integrated, multimode gel and Western blot imager with chemiluminescent, fluorescent, and infrared detection capabilities. 

The FluorChem R system takes Western blot imaging to the next level by combining three key elements — application flexibility, sensitivity and ease-of-use. Its 8.3 megapixel CCD camera and simple 10.4 inch touch screen interface allow researchers to detect even the faintest band — and get crisp, clear images every time. Like the preceding FluorChem products, it is equipped with an on-board computer and intuitive browser-based Digital Darkroom acquisition and analysis software, so the FluorChem R system is ready to use right out the box.

"The FluorChem R system brings together three detection modes in a single instrument, making it the 'do all' instrument in the gel and blot imaging space today," commented John Proctor, Director of Marketing at ProteinSimple. "The multimode capability of the FluorChem R system will enable researchers to use a broad array of secondary antibodies and dyes without additional instruments or reagents; ultimately maximizing laboratory bench space."

Read more: http://www.proteinsimple.com/news_details.html?id=47&page=news.html

San Diego, California, July 10, 2013 — ViaCyte, Inc., a leading regenerative medicine company focused on developing new approaches to treat major diseases through the application of a stem cell-derived cell therapy, announced today that it completed a private equity financing transaction, providing the Company $10.6 million through the sale of Series C-1 Preferred Stock, together with warrants to purchase stock.  The financing, conducted as a rights offering to ViaCyte Series B and C Preferred Stock holders, included the Company’s largest existing investors – Johnson & Johnson Development Corporation, Sanderling Ventures and Asset Management Company (Johnson Trust).

This funding serves as a match for a $10.1 million Strategic Partnership Award (SPA) that was approved last October by the California Institute for Regenerative Medicine (CIRM) to support clinical evaluation of VC-01, ViaCyte’s promising encapsulated cell-therapy product being developed as a transformative therapy for patients with type 1 and insulin-dependent type 2 diabetes.  In addition, ViaCyte may sell additional shares of Series C-1 Preferred Stock and warrants in one or more subsequent closings that may occur during the remainder of 2013.

The Company will use the funds to pursue clinical development of VC-01. VC-01 is a development-stage product that consists of pancreatic precursor cells (designated PEC-01) manufactured through directed differentiation of stem cells sourced from a proprietary human embryonic stem cell line, and encapsulated in a proprietary, immune protective medical device (the ENCAPTRA® device).  When implanted under the skin, the encapsulated cells are designed to further differentiate into insulin and other hormone-producing pancreatic cells that regulate blood glucose in a manner similar or identical to a normal pancreas.

Read more: http://viacyte.com/press-releases/viacyte-inc-raises-10-6-million-in-a-private-financing-to-support-clinical-development-of-its-cell-therapy-product-for-insulin-dependent-diabetes/

Judy Twist shares with Lisa her success with the program Prevent. 
 
Prevent is a 16-week online program designed to help people lose weight and reduce their risk of type 2 diabetes. We combine a clinically-proven curriculum with individual mentorship to guide participants toward manageable but powerful goals.

http://omadahealth.com/programs/diabetes-prevention/

Listen here.